BIVF et al. back CHF 25m round for T3 Pharmaceuticals
Existing investors Boehringer Ingelheim Venture Fund (BIVF), Reference Capital, multi-family office Wille Finance and several private investors have backed a CHF 25m round for cancer therapy developer T3 Pharmaceuticals.